...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >CAR T-Cell Therapy: Adverse Events and Management
【24h】

CAR T-Cell Therapy: Adverse Events and Management

机译：汽车T细胞疗法：不良事件和管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chimeric antigen receptor (CAR) T-cell therapy is an exciting innovation in the treatment of cancer. However, CAR T-cell therapies have been associated with unique adverse events (AEs), including cytokine release syndrome (CRS) and neurologic events (also known as CAR T-tell-related encephalopathy syndrome [CRES] or, most recently, immune effector cell-associated neurotoxicity syndrome [ICANS]). Cyto-penias and infection have also been observed. These AEs are treatable and reversible with appropriate treatment strategies but can become severe if not managed early. Therefore, it is essential for the advanced practitioner caring for patients undergoing these therapies to have a thorough understanding of the associated AEs, in particular their grading and management. Cytokine release syndrome and neurologic events can range in severity from low-grade symptoms that require supportive care only to a high-grade syndrome that can become life-threatening. While several grading and management recommendations have been used in clinical trials, until recently, there were no consistent grading and management guidelines. Here we provide the most recent recommendations, which have the ultimate goal of maintaining the benefits of CAR T-cell therapy, while minimizing life-threatening AEs. Improved understanding and management of AEs associated with CAR T-cell therapy will provide broader access to this innovative and potentially curative technology.
机译：嵌合抗原受体（轿车）T细胞疗法是治疗癌症的令人兴奋的创新。然而，汽车T细胞疗法与独特的不良事件（AES）有关，包括细胞因子释放综合征（CRS）和神经系统事件（也称为Car T-relet-informshalocathy综合征[Cres]或，最近，免疫效应细胞相关神经毒性综合征[ICAN]）。也观察到细胞灵敏和感染。这些AES可与适当的治疗策略进行治疗和可逆，但如果未提前管理，可能会变得严重。因此，对经过这些疗法的患者进行高级医生关怀至关重要，以彻底了解相关的AES，特别是他们的评分和管理。细胞因子释放综合征和神经学事件可以严重程度地从低级症状的严重程度，需要支持的高级综合征，这可能成为危及生命的综合症。虽然在临床试验中使用了几种评分和管理建议，但直到最近，没有一致的分级和管理指南。在这里，我们提供最近的建议，这具有保持汽车T细胞疗法的益处的最终目标，同时最大限度地减少危及生命的AES。改善与汽车T细胞疗法相关的AE的理解和管理将提供更广泛的访问这种创新和潜在的治疗技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号